TCI Wealth Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

TCI Wealth Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-500	Closed	-$455	–	666
2023 Q1	$455	Hold	500	–	–	﹤0.01%	2229
2022 Q4	$425	Sell	500 -300	-38%	-$265	﹤0.01%	2243
2022 Q3	$1K	Hold	800	–	–	﹤0.01%	2062
2022 Q2	$1K	Buy	800 +400	+100%	+$491	﹤0.01%	2110
2022 Q1	$1K	Hold	400	–	–	﹤0.01%	2083
2021 Q4	$1K	Buy	400 +100	+33%	+$388	﹤0.01%	2175
2021 Q3	$1K	Buy	+300	New	+$888	﹤0.01%	2245

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

TCI Wealth Advisors's CRVS Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q2 2023, closing a stake of 500 shares — an estimated $455 sold.

TCI Wealth Advisors first reported a position in CRVS in Q3 2021 and held it in 7 quarters. The position peaked at $1K in Q3 2022. 52 funds tracked by Wall St. Rank hold CRVS as of Q2 2023.

TCI Wealth Advisors reported no remaining Corvus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 500 Corvus Pharmaceuticals shares in Q2 2023, an estimated $455.
TCI Wealth Advisors first reported a position in Corvus Pharmaceuticals in Q3 2021 and held it in 7 quarters.
TCI Wealth Advisors's Corvus Pharmaceuticals position peaked at $1K in Q3 2022.
52 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.